SEMAGLUTIDE | N213051 | NOVO NORDISK INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2023-00722 | 8536122 | IPR | Mylan Pharmaceuticals Inc. et al. | Institution Denied | 2023-03-16 | 2023-10-02 |
| IPR2023-00723 | 8129343 | IPR | Mylan Pharmaceuticals Inc. et al. | Institution Denied | 2023-03-16 | 2023-10-02 |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2026-02-20 | Terminated 2026-03-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 8129343 | Dec 5, 2031 | — | Yes | Yes | — | |
| 8536122 | Mar 20, 2026 | — | Yes | Yes | — | |
| 9278123 | Dec 16, 2031 | — | — | Yes | — | |
| 10086047 | Dec 16, 2031 | — | — | Yes | — | — |
| 10278923 | May 2, 2034 | — | — | — | — | |
| 10933120 | Mar 15, 2033 | — | — | Yes | — | — |
| 10960052 | Dec 16, 2031 | — | — | Yes | — | — |
| 11033499 | Jun 19, 2033 | — | — | Yes | — | |
| 11382957 | Dec 16, 2031 | — | — | Yes | — | — |
| 11759501 | Mar 15, 2033 | — | — | Yes | — | — |
| 11759502 | Mar 15, 2033 | — | — | Yes | — | — |
| 11759503 | Mar 15, 2033 | — | — | Yes | — | — |
| 12239739 | May 2, 2034 | — | Yes | Yes | — | |
| 12514822 | May 2, 2034 | — | — | — | — | |
| 12594326 | Mar 15, 2033 | — | — | Yes | — | — |
| Code | Date | Status |
|---|---|---|
| I-976 | Oct 17, 2028 | Active |
Novo Nordisk added U.S. Patent 11,033,499 to the Orange Book for RYBELSUS (semaglutide) oral tablets.
New: New record
Novo Nordisk added US Patent 11,033,499 to the Orange Book for Rybelsus (semaglutide) oral formulation.
New: New record
Novo Nordisk added patent 11033499 to the Orange Book for Rybelsus (semaglutide) oral tablets, NDA 213051.
New: New record
Novo Nordisk added patent 11,033,499 to the Orange Book listing for Rybelsus (semaglutide) oral formulation.
New: New record
Novo Nordisk added U.S. Patent 11,033,499 to the Orange Book listing for Rybelsus (semaglutide) oral formulation.
New: New record
Novo Nordisk added patent '11033499' to the Orange Book listing for Rybelsus (semaglutide) oral formulation.
New: New record